Patents by Inventor Kimberly Vanover

Kimberly Vanover has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds and methods
    Patent number: 11958852
    Abstract: The present invention relates to use of particular substituted heterocycle fused gamma-carbolines as described herein, in free, pharmaceutically acceptable salt or prodrug form, and pharmaceutical composition comprising the same optionally in combination with one or more agents, for the prophylaxis or treatment of one or more disorders associated with dementia, particularly behavioral or mood disturbances (e.g., agitation/aggression), psychosis, depression and sleep disturbances among others in patients suffering from dementia.
    Type: Grant
    Filed: August 18, 2021
    Date of Patent: April 16, 2024
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Sharon Mates, Robert Davis, Kimberly Vanover, Lawrence Wennogle
  • NOVEL METHODS
    Publication number: 20240066030
    Abstract: The disclosure provides methods for the treatment of Bipolar II Disorder, comprising administering to a patient in need thereof, a therapeutically effective amount of lumateperone, in free or pharmaceutically acceptable salt form, optionally in deuterated form.
    Type: Application
    Filed: October 25, 2023
    Publication date: February 29, 2024
    Applicant: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Sharon MATES, Robert DAVIS, Kimberly VANOVER
  • ORGANIC COMPOUNDS
    Publication number: 20240059687
    Abstract: The invention relates to particular prodrugs of substituted heterocycle fused gamma-carbolines, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the ?-opioid receptor.
    Type: Application
    Filed: August 17, 2023
    Publication date: February 22, 2024
    Inventors: Peng LI, Hailin ZHENG, Robert DAVIS, Sharon MATES, Kimberly VANOVER, Gretchen SNYDER
  • NOVEL METHODS
    Publication number: 20240024334
    Abstract: The disclosure provides the use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of residual symptoms of psychosis or schizophrenia. The disclosure also provides novel long acting injectable formulations of particular substituted heterocycle fused gamma-carboline compounds and use of such long acting injectable formulations for the treatment of residual symptoms of psychosis or schizophrenia.
    Type: Application
    Filed: October 4, 2023
    Publication date: January 25, 2024
    Applicant: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Kimberly VANOVER, Peng LI, Sharon MATES, Robert DAVIS, Lawrence P. WENNOGLE
  • PHARMACEUTICAL COMPOSITIONS COMPRISING 4-((6bR,10aS)-3-METHYL2,3,6b,9,10,10a-HEXAHYDRO-1H-PYRIDO[3',4':4,5]PYRROLO[1,2,3-de]QUINOXALIN8(7H)-YL)-1-(4-((6bR,10aS)-3-METHYL-2,3,6b,9,10,10a-HEXAHYDRO-1HPYRIDO[3',4':4,5]PYRROLO[1,2,3-de]QUINOXALIN-8(7H)-YL)PHENYL)BUTAN-1-ONE FOR TREATING CONDITIONS OF THE CENTRAL NERVOUS SYSTEM AND CARDIAC DISORDERS
    Publication number: 20240002403
    Abstract: The invention relates to pharmaceutical compositions comprising the compound of Formula I, and new methods and uses pertaining thereto, and pharmaceutical compositions thereof, such as methods of use in the treatment of diseases involving the 5-HT receptor, the serotonin transporter (SERT), and/or pathways involving dopamine D2 receptor signaling, sodium channel activity, and/or norepinephrine transporter activity.
    Type: Application
    Filed: August 31, 2023
    Publication date: January 4, 2024
    Inventors: Peng LI, Robert E DAVIS, Kimberly Vanover
  • Organic compounds
    Patent number: 11844757
    Abstract: The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the ?-opioid receptor.
    Type: Grant
    Filed: September 9, 2020
    Date of Patent: December 19, 2023
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Wei Yao, Peng Li, Robert Davis, Sharon Mates, Kimberly Vanover, Gretchen Snyder
  • METHODS OF TREATMENT
    Publication number: 20230355625
    Abstract: The present disclosure relates to inhibitors of phosphodiesterase 1 (PDE1) useful for the engagement with the central nervous system. The disclosure further relates to the administration of inhibitors of phosphodiesterase 1 (PDE1) for the treatment of a condition, disease or disorder associated with the dopamine D1 receptor intracellular pathway, e.g., a condition, disease or disorder characterized by a deficit in attention, cognition, memory and/or inhibitory processing.
    Type: Application
    Filed: November 25, 2020
    Publication date: November 9, 2023
    Inventors: Kimberly VANOVER, Robert DAVIS, Peng LI
  • Organic compounds
    Patent number: 11773095
    Abstract: The invention relates to particular prodrugs of substituted heterocycle fused gamma-carbolines, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the ?-opioid receptor.
    Type: Grant
    Filed: July 19, 2022
    Date of Patent: October 3, 2023
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Peng Li, Hailin Zheng, Robert Davis, Sharon Mates, Kimberly Vanover, Gretchen Snyder
  • 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3?4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disorders
    Patent number: 11753419
    Abstract: The invention relates to a particular substituted heterocycle fused gamma carboline, the compound of Formula I, and new methods and uses pertaining thereto, and pharmaceutical compositions thereof, such as methods of use in the treatment of diseases involving the 5-HT receptor, the serotonin transporter (SERT), and/or pathways involving dopamine D2 receptor signaling, sodium channel activity, and/or norepinephrine transporter activity.
    Type: Grant
    Filed: December 10, 2020
    Date of Patent: September 12, 2023
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Peng Li, Robert E Davis, Kimberly Vanover
  • ORGANIC COMPOUNDS
    Publication number: 20230181576
    Abstract: The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the ?-opioid receptor.
    Type: Application
    Filed: September 9, 2020
    Publication date: June 15, 2023
    Applicant: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Wei YAO, Peng LI, Robert DAVIS, Sharon MATES, Kimberly VANOVER, Gretchen SNYDER
  • ORGANIC COMPOUND
    Publication number: 20230021717
    Abstract: The invention relates to a particular substituted heterocycle fused gamma-carboline, the compound of Formula I, and new methods and uses pertaining thereto, and pharmaceutical compositions thereof, such as methods of use in the treatment of diseases involving the 5-HT receptor, the serotonin transporter (SERT), and/or pathways involving dopamine D2 receptor signaling, sodium channel activity, and/or norepinephrine transporter activity.
    Type: Application
    Filed: December 10, 2020
    Publication date: January 26, 2023
    Inventors: Peng LI, Robert E DAVIS, Kimberly Vanover
  • ORGANIC COMPOUNDS
    Publication number: 20220372035
    Abstract: The invention relates to particular prodrugs of substituted heterocycle fused gamma-carbolines, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the ?-opioid receptor.
    Type: Application
    Filed: July 19, 2022
    Publication date: November 24, 2022
    Inventors: Peng LI, Hailin ZHENG, Robert DAVIS, Sharon MATES, Kimberly VANOVER, Gretchen SNYDER
  • ORGANIC COMPOUNDS
    Publication number: 20220296591
    Abstract: The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the ?-opioid receptor.
    Type: Application
    Filed: June 3, 2022
    Publication date: September 22, 2022
    Inventors: Peng LI, Wei YAO, Robert DAVIS, Sharon MATES, Kimberly VANOVER, Gretchen SNYDER
  • Organic compounds
    Patent number: 11427587
    Abstract: The invention relates to particular prodrugs of substituted heterocycle fused gamma-carbolines, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the ?-opioid receptor.
    Type: Grant
    Filed: July 20, 2018
    Date of Patent: August 30, 2022
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Peng Li, Hailin Zheng, Robert Davis, Sharon Mates, Kimberly Vanover, Gretchen Snyder
  • Organic compounds
    Patent number: 11376249
    Abstract: The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the ?-opioid receptor.
    Type: Grant
    Filed: July 20, 2018
    Date of Patent: July 5, 2022
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Peng Li, Wei Yao, Robert Davis, Sharon Mates, Kimberly Vanover, Gretchen Snyder
  • METHODS OF TREATING NEUROPATHIC PAIN
    Publication number: 20220184072
    Abstract: The invention relates to particular substituted heterocycle fused gamma-carbolines, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, for use in methods for the treatment of neuropathic pain.
    Type: Application
    Filed: April 4, 2020
    Publication date: June 16, 2022
    Inventors: Robert DAVIS, Gretchen SNYDER, Kimberly VANOVER
  • METHODS OF TREATING ADDICTION
    Publication number: 20220088014
    Abstract: The invention relates to particular substituted heterocycle fused gamma-carbolines, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, for use in methods for the treatment or prevention of opiate addiction relapse.
    Type: Application
    Filed: January 23, 2020
    Publication date: March 24, 2022
    Inventors: Peng LI, Wei YAO, Robert DAVIS, Sharon MATES, Kimberly VANOVER, Gretchen SNYDER
  • ORGANIC COMPOUNDS
    Publication number: 20220073558
    Abstract: The invention relates to particular prodrugs and analogs of (3?,5?)-3-hydroxy-21-(1H-imidazol-1-yl)-3-methoxymethyl)-pregnan-20-one, in free or pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use as sedatives, hypnotics, anxiolytics, and/or anesthetics, and methods for treatment of depression, anxiety, insomnia, epilepsy, and other central nervous system disorders, as well as to combinations with other agents.
    Type: Application
    Filed: December 17, 2019
    Publication date: March 10, 2022
    Inventors: Kimberly VANOVER, Peng LI, Robert DAVIS, Yupu QIAO
  • ORGANIC COMPOUNDS
    Publication number: 20220056031
    Abstract: The invention relates to a particular enantiomer of a substituted heterocycle fused gamma-carboline, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, and pathways involving the dopamine D1 and D2 receptor signaling system.
    Type: Application
    Filed: December 20, 2019
    Publication date: February 24, 2022
    Inventors: Peng LI, Kimberly VANOVER, Robert DAVIS
  • NOVEL COMPOUNDS AND METHODS
    Publication number: 20210371421
    Abstract: The present invention relates to use of particular substituted heterocycle fused gamma-carbolines as described herein, in free, pharmaceutically acceptable salt or prodrug form, and pharmaceutical composition comprising the same optionally in combination with one or more agents, for the prophylaxis or treatment of one or more disorders associated with dementia, particularly behavioral or mood disturbances (e.g., agitation/aggression), psychosis, depression and sleep disturbances among others in patients suffering from dementia.
    Type: Application
    Filed: August 18, 2021
    Publication date: December 2, 2021
    Applicant: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Sharon MATES, Robert DAVIS, Kimberly VANOVER, Lawrence WENNOGLE